Antibody Dermatology Insulin 
XTalks
AUGUST 2, 2023
2) Darzalex (daratumumab) Darzalex is a targeted monoclonal antibody that slows or stops the progression of multiple myeloma (a blood cancer) by binding to the CD38 protein on multiple myeloma cells. The monoclonal antibody targets CD20, a protein found on the surface of B lymphocytes (B cells). billion in 2022, a 32.44
The Pharma Data
AUGUST 17, 2021
About JEMPERLI (dostarlimab-gxly) JEMPERLI is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. The collaboration has resulted in three monospecific antibody therapies that have progressed into the clinic. Immune-Mediated Pneumonitis.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JULY 23, 2021
endocrinopathies and dermatologic reactions) are discussed below. Monitor patients for hyperglycemia or other signs and symptoms of diabetes; initiate treatment with insulin as clinically indicated. Immune-Mediated Dermatologic Adverse Reactions OPDIVO can cause immune-mediated rash or dermatitis.
The Pharma Data
APRIL 4, 2023
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Initiate treatment with insulin as clinically indicated. See additional selected indications for KEYTRUDA in the U.S.
The Pharma Data
MARCH 11, 2021
endocrinopathies and dermatologic reactions) are discussed below. Monitor patients for hyperglycemia or other signs and symptoms of diabetes; initiate treatment with insulin as clinically indicated. Immune-Mediated Dermatologic Adverse Reactions. Immune-Mediated Pneumonitis. OPDIVO can cause immune-mediated rash or dermatitis.
Expert insights. Personalized for you.
98 
Let's personalize your content